Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 744-751

  Pabary, Rishi ^a,b   Singh, Charanjit ^a   Morales, Sandra ^c   Bush, Andrew ^a,b   Alshafi, Khalid ^b   Bilton, Diana ^b   Alton, Eric W F W ^a   Smithyman, Anthony ^c   Davies, Jane C ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c Special Phage Services   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; INTERLEUKIN 10; INTERLEUKIN 1BETA; KERATINOCYTE CHEMOATTRACTANT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIUM ISOLATE; BRONCHOALVEOLAR LAVAGE FLUID; CONTROLLED STUDY; FEMALE; INFECTION PREVENTION; INFLAMMATORY CELL; KERATINOCYTE; LEUKOCYTE DIFFERENTIAL COUNT; MOUSE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INFLAMMATION; LUNG; MICROBIOLOGY; NEUTROPHIL; PSEUDOMONAS INFECTIONS; VIROLOGY;

ANIMALS; BACTERIAL LOAD; BACTERIOPHAGES; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; LUNG; MICE; MICE, INBRED BALB C; NEUTROPHILS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84957900614     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01426-15     Document Type: Article

References (55)

1. World Health Organization. 2013. Antimicrobial resistance. http://www.who.int/mediacentre/factsheets/fs194/en/.
2. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:91-100. http://dx.doi.org/10.1002/ppul.10127.
3. Langton Hewer SC, Smyth AR. 2009. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 4:CD004197.
4. Poole K. 2001. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 3:255-264.
5. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34:634-640. http://dx.doi.org/10.1086/338782.
6. Rao S, Grigg J. 2006. New insights into pulmonary inflammation in cystic fibrosis. Arch Dis Child 91:786-788. http://dx.doi.org/10.1136/adc.2004.069419.
7. Downey DG, Bell SC, Elborn JS. 2009. Neutrophils in cystic fibrosis. Thorax 64:81-88. http://dx.doi.org/10.1136/thx.2007.082388.
8. Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. 2003. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 168:1471-1475. http://dx.doi.org/10.1164/rccm.200306-731OC.
9. O'Toole GA, Kolter R. 1998. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 30:295-304. http://dx.doi.org/10.1046/j.1365-2958.1998.01062.x.
10. Nordmann P, Naas T, Fortineau N, Poirel L. 2007. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 10:436-440. http://dx.doi.org/10.1016/j.mib.2007.07.004.
11. Bradbury J. 2004. "My enemy's enemy is my friend." Using phages to fight bacteria. Lancet 363:624-625. http://dx.doi.org/10.1016/S0140-6736( 04)15629-8.
12. Fruciano DE, Bourne S. 2007. Phage as an antimicrobial agent: d'Herelle's heretical theories and their role in the decline of phage prophylaxis in the West. Can J Infect Dis Med Microbiol 18:19-26.
13. Łobocka M, Szybalski WT. 2012. Advances in virus research. Bacteriophages, part A. Preface. Adv Virus Res 82:xiii-xv.
14. Fleming A. 1929. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 10:226-236.
15. Kutateladze M, Adamia R. 2008. Phage therapy experience at the Eliava Institute. Med Mal Infect 38:426-430. http://dx.doi.org/10.1016/j.medmal.2008.06.023.
16. Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ. 2008. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 104:1-13. http://dx.doi.org/10.1111/j.1365-2672.2007.03498.x.
17. Thiel K. 2004. Old dogma, new tricks-21st century phage therapy. Nat Biotechnol 22:31-36. http://dx.doi.org/10.1038/nbt0104-31.
18. Sillankorva SM, Oliveira H, Azeredo J. 2012. Bacteriophages and their role in food safety. Int J Microbiol 2012:863945. http://dx.doi.org/10.1155/2012/863945.
19. Greer GG. 2005. Bacteriophage control of foodborne bacteria. J Food Prot 68:1102-1111.
20. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. 2010. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54:397-404. http://dx.doi.org/10.1128/AAC.00669-09.
21. Meitert E, Petrovici M, Sima F, Costache G, Savulian C. 1987. Investigation on the therapeutical efficiency of some adapted bacteriophages in experimental infection with Pseudomonas aeruginosa. Arch Roum Pathol Exp Microbiol 46:17-26.
22. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ, Hu J. 2006. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 17:309-317.
23. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201:1096-1104. http://dx.doi.org/10.1086/651135.
24. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. 2011. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 6:e16963. http://dx.doi.org/10.1371/journal.pone.0016963.
25. Craig A, Mai J, Cai S, Jeyaseelan S. 2009. Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun 77:568-575. http://dx.doi.org/10.1128/IAI.00832-08.
26. Jones AM, Martin L, Bright-Thomas RJ, Dodd ME, McDowell A, Moffitt KL, Elborn JS, Webb AK. 2003. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur Respir J 22:503-506. http://dx.doi.org/10.1183/09031936.03.00004503.
27. Golshahi L, Seed KD, Dennis JJ, Finlay WH. 2008. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv 21:351-360. http://dx.doi.org/10.1089/jamp.2008.0701.
28. Wright A, Hawkins CH, Anggard EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349-357. http://dx.doi.org/10.1111/j.1749-4486.2009.01973.x.
29. Fortuna W, Miedzybrodzki R, Weber-Dabrowska B, Gorski A. 2008. Bacteriophage therapy in children: facts and prospects. Med Sci Monit 14:RA126-RA132.
30. Kutter ESA. 2004. Bacteriophages: biology and applications. CRC Press, Boca Raton, FL.
31. Finney M. 2001. Pulsed-field gel electrophoresis. Curr Protoc Mol Biol Chapter 2:Unit 2.5B. http://dx.doi.org/10.1002/0471142727.mb0205bs51.
32. Adams MH. 1959. Bacteriophages. Interscience Publishers Inc., New York, NY.
33. Holloway BW. 1955. Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 13:572-581. http://dx.doi.org/10.1099/00221287-13-3-572.
34. Klockgether J, Munder A, Neugebauer J, Davenport CF, Stanke F, Larbig KD, Heeb S, Schöck U, Pohl TM, Wiehlmann L, Tümmler B. 2010. Genome diversity of Pseudomonas aeruginosa PAO1 laboratory strains. J Bacteriol 192:1113-1121. http://dx.doi.org/10.1128/JB.01515-09.
35. Miles AA, Misra SS, Irwin JO. 1938. The estimation of the bactericidal power of the blood. J Hyg (Lond) 38:732-749. http://dx.doi.org/10.1017/S002217240001158X.
36. Henry M, Lavigne R, Debarbieux L. 2013. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 57:5961-5968. http://dx.doi.org/10.1128/AAC.01596-13.
37. Bull JJ, Gill JJ. 2014. The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages. Front Microbiol 5:618. http://dx.doi.org/10.3389/fmicb.2014.00618.
38. Morissette C, Skamene E, Gervais F. 1995. Endobronchial inflammation following Pseudomonas aeruginosa infection in resistant and susceptible strains of mice. Infect Immun 63:1718-1724.
39. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075-1082. http://dx.doi.org/10.1164/ajrccm.151.4.7697234.
40. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, Smith A, Martin TR, Ramsey BW. 2001. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 32:356-366. http://dx.doi.org/10.1002/ppul.1144.
41. Segel GB, Halterman MW, Lichtman MA. 2011. The paradox of the neutrophil's role in tissue injury. J Leukoc Biol 89:359-372. http://dx.doi.org/10.1189/jlb.0910538.
42. Konstan MW, Doring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton A. 2014. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 13:148-155. http://dx.doi.org/10.1016/j.jcf.2013.12.009.
43. van Furth R, van Zwet TL, Buisman AM, van Dissel JT. 1994. Antitumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J Infect Dis 170:234-237. http://dx.doi.org/10.1093/infdis/170.1.234.
44. Staugas RE, Harvey DP, Ferrante A, Nandoskar M, Allison AC. 1992. Induction of tumor necrosis factor (TNF) and interleukin-1 (IL-1) by Pseudomonas aeruginosa and exotoxin A-induced suppression of lymphoproliferation and TNF, lymphotoxin, gamma interferon, and IL-1 production in human leukocytes. Infect Immun 60:3162-3168.
45. Hedges S, Svensson M, Svanborg C. 1992. Interleukin-6 response of epithelial cell lines to bacterial stimulation in vitro. Infect Immun 60:1295-1301.
46. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. 2003. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14:361-368. http://dx.doi.org/10.1016/S1359-6101( 03)00043-1.
47. Rovai LE, Herschman HR, Smith JB. 1998. The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocorticoid regulation in endotoxemia. J Leukoc Biol 64:494-502.
48. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey A, Ross RP, Hill C. 2012. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. mBio 3:e00029-12. http://dx.doi.org/10.1128/mBio.00029-12.
49. Lu TK, Collins JJ. 2007. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104:11197-11202. http://dx.doi.org/10.1073/pnas.0704624104.
50. Hughes KA, Sutherland IW, Jones MV. 1998. Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Microbiology 144(Pt 11):3039-3047. http://dx.doi.org/10.1099/00221287-144-11-3039.
51. Zhang Y, Hu Z. 2013. Combined treatment of Pseudomonas aeruginosa biofilms with bacteriophages and chlorine. Biotechnol Bioeng 110:286-295. http://dx.doi.org/10.1002/bit.24630.
52. Couper KN, Blount DG, Riley EM. 2008. IL-10: the master regulator of immunity to infection. J Immunol 180:5771-5777. http://dx.doi.org/10.4049/jimmunol.180.9.5771.
53. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. 2009. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 9:447-453. http://dx.doi.org/10.1016/j.coph.2009.04.008.
54. Cystic Fibrosis Trust. 2013. Annual UK CF registry data report 2013, p 25-26. http://www.cysticfibrosis.org.uk/media/598466/annual-data-report-2013-jul14.pdf.
55. Sulakvelidze A, Alavidze Z, Morris JG, Jr. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45:649-659. http://dx.doi.org/10.1128/AAC.45.3.649-659.2001.